B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology ...

@article{2251387,
   author = {Infante, Maria Stefania and SalmantonandGarcia, Jon and FernandezandCruz, Ana and Marchesi, Francesco and Jaksic, Ozren and Weinbergerová, Barbora and Besson, Caroline and Duarte, Rafael F and Itri, Federico and Valkovic, Toni and Szotkovski, Tomas and Busca, Alessandro and Guidetti, Anna and Glenthoj, Andreas and Collins, Graham P and Bonuomo, Valentina and Sili, Uluhan and Seval, Guldane Cengiz and Machado, Marina and Cordoba, Raul and Blennow, Ola and AbuandZeinah, Ghaith and Lamure, Sylvain and Kulasekararaj, Austin and FalcesandRomero, Iker and Cattaneo, Chiara and Jaap, Van Doesum and Piukovics, Klara and Omrani, Ali S and Magliano, Gabriele and Ledoux, MarieandPierre and Cristina, de Ramon and Cabirta, Alba and Verga, Luisa and LopezandGarcia, Alberto and Gomes, Da Silva Maria and Stojanoski, Zlate and Meers, Stef and Lahmer, Tobias and MartinandPerez, Sonia and DavilaandVals, Julio and Jens, Van Praet and Samarkos, Michail and Bilgin, Yavuz M and Karlsson, Linda Katharina and Batinic, Josip and Nordlander, Anna and Schonlein, Martin and Hoenigl, Martin and Racil, Zdenek and Mladenovic, Milos and Hanakova, Michaela and Zambrotta, Giovanni Paolo Maria and Nick, De Jonge and AdzicandVukicevic, Tatjana and NunesandRodrigues, Raquel and Prezioso, Lucia and Navratil, Milan and Marchetti, Monia and Cuccaro, Annarosa and Calbacho, Maria and Giordano, Antonio and Cornely, Oliver A and HernandezandRivas, JoseandAngel and Pagano, Livio},
   article_location = {Lausanne},
   article_number = {October 2022},
   doi = {http://dx.doi.org/10.3389/fonc.2022.992137},
   keywords = {SARS-CoV-2; targeted drugs; infection risk; immune system COVID19; lymphoproliferative diseases (LPD); chronic lymphocytic leukemia (CLL); non-Hodgkin lymphoma (NHL)},
   language = {eng},
   issn = {2234-943X},
   journal = {Frontiers in Oncology},
   title = {B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)},
   url = {https://www.frontiersin.org/articles/10.3389/fonc.2022.992137/full},
   volume = {12},
   year = {2022}
}

TY  - JOUR
ID  - 2251387
AU  - Infante, Maria Stefania - Salmanton-Garcia, Jon - Fernandez-Cruz, Ana - Marchesi, Francesco - Jaksic, Ozren - Weinbergerová, Barbora - Besson, Caroline - Duarte, Rafael F - Itri, Federico - Valkovic, Toni - Szotkovski, Tomas - Busca, Alessandro - Guidetti, Anna - Glenthoj, Andreas - Collins, Graham P - Bonuomo, Valentina - Sili, Uluhan - Seval, Guldane Cengiz - Machado, Marina - Cordoba, Raul - Blennow, Ola - Abu-Zeinah, Ghaith - Lamure, Sylvain - Kulasekararaj, Austin - Falces-Romero, Iker - Cattaneo, Chiara - Jaap, Van Doesum - Piukovics, Klara - Omrani, Ali S - Magliano, Gabriele - Ledoux, Marie-Pierre - Cristina, de Ramon - Cabirta, Alba - Verga, Luisa - Lopez-Garcia, Alberto - Gomes, Da Silva Maria - Stojanoski, Zlate - Meers, Stef - Lahmer, Tobias - Martin-Perez, Sonia - Davila-Vals, Julio - Jens, Van Praet - Samarkos, Michail - Bilgin, Yavuz M - Karlsson, Linda Katharina - Batinic, Josip - Nordlander, Anna - Schonlein, Martin - Hoenigl, Martin - Racil, Zdenek - Mladenovic, Milos - Hanakova, Michaela - Zambrotta, Giovanni Paolo Maria - Nick, De Jonge - Adzic-Vukicevic, Tatjana - Nunes-Rodrigues, Raquel - Prezioso, Lucia - Navratil, Milan - Marchetti, Monia - Cuccaro, Annarosa - Calbacho, Maria - Giordano, Antonio - Cornely, Oliver A - Hernandez-Rivas, Jose-Angel - Pagano, Livio
PY  - 2022
TI  - B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)
JF  - Frontiers in Oncology
VL  - 12
IS  - October 2022
SP  - 1-17
EP  - 1-17
PB  - Frontiers Media S.A.
SN  - 2234943X
KW  - SARS-CoV-2
KW  - targeted drugs
KW  - infection risk
KW  - immune system COVID19
KW  - lymphoproliferative diseases (LPD)
KW  - chronic lymphocytic leukemia (CLL)
KW  - non-Hodgkin lymphoma (NHL)
UR  - https://www.frontiersin.org/articles/10.3389/fonc.2022.992137/full
N2  - Patients with lymphoproliferative diseases (LPD) are vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Here, we describe and analyze the outcome of 366 adult patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin Lymphoma (NHL) treated with targeted drugs and laboratory-confirmed COVID-19 diagnosed between February 2020 and January 2022. Median follow-up was 70.5 days (IQR 0-609). Most used targeted drugs were Bruton-kinase inhibitors (BKIs) (N= 201, 55%), anti-CD20 other than rituximab (N=61, 16%), BCL2 inhibitors (N=33, 9%) and lenalidomide (N=28, 8%).Only 16.2% of the patients were vaccinated with 2 or more doses of vaccine at the onset of COVID-19. Mortality was 24% (89/366) on day 30 and 36%(134/366) on the last day of follow-up. Age >75 years (p<0.001, HR 1.036), active malignancy (p<0.001, HR 2.215), severe COVID-19 (p=0.017, HR 2.270) and admission to ICU (p<0.001, HR 5.751) were risk factors for mortality at last day of follow up. There was no difference in OS rates in NHL vs CLL patients (p=0.306), nor in patients treated with or without BKIs (p=0.151). Mortality in ICU was 66% (CLL 61%, NHL 76%). Overall mortality rate decreased according to vaccination status, being 39% in unvaccinated patients, 32% and 26% in those having received one or two doses, respectively, and 20% in patients with a booster dose (p=0.245). Overall mortality rate dropped from 41% during the first semester of 2020 to 25% at the last semester of 2021. These results show increased severity and mortality from COVID-19 in LPDs patients treated with targeted drugs.
ER  - 

INFANTE, Maria Stefania, Jon SALMANTON-GARCIA, Ana FERNANDEZ-CRUZ, Francesco MARCHESI, Ozren JAKSIC, Barbora WEINBERGEROVÁ, Caroline BESSON, Rafael F DUARTE, Federico ITRI, Toni VALKOVIC, Tomas SZOTKOVSKI, Alessandro BUSCA, Anna GUIDETTI, Andreas GLENTHOJ, Graham P COLLINS, Valentina BONUOMO, Uluhan SILI, Guldane Cengiz SEVAL, Marina MACHADO, Raul CORDOBA, Ola BLENNOW, Ghaith ABU-ZEINAH, Sylvain LAMURE, Austin KULASEKARARAJ, Iker FALCES-ROMERO, Chiara CATTANEO, Van Doesum JAAP, Klara PIUKOVICS, Ali S OMRANI, Gabriele MAGLIANO, Marie-Pierre LEDOUX, de Ramon CRISTINA, Alba CABIRTA, Luisa VERGA, Alberto LOPEZ-GARCIA, Da Silva Maria GOMES, Zlate STOJANOSKI, Stef MEERS, Tobias LAHMER, Sonia MARTIN-PEREZ, Julio DAVILA-VALS, Van Praet JENS, Michail SAMARKOS, Yavuz M BILGIN, Linda Katharina KARLSSON, Josip BATINIC, Anna NORDLANDER, Martin SCHONLEIN, Martin HOENIGL, Zdenek RACIL, Milos MLADENOVIC, Michaela HANAKOVA, Giovanni Paolo Maria ZAMBROTTA, De Jonge NICK, Tatjana ADZIC-VUKICEVIC, Raquel NUNES-RODRIGUES, Lucia PREZIOSO, Milan NAVRATIL, Monia MARCHETTI, Annarosa CUCCARO, Maria CALBACHO, Antonio GIORDANO, Oliver A CORNELY, Jose-Angel HERNANDEZ-RIVAS and Livio PAGANO. B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA). \textit{Frontiers in Oncology}. Lausanne: Frontiers Media S.A., 2022, vol.~12, October 2022, p.~1-17. ISSN~2234-943X. Available from: https://dx.doi.org/10.3389/fonc.2022.992137.